April 27, 2024

Archives for March 2011

W.T.O. Rules U.S. Subsidies for Boeing Unfair

Washington said it was considering an appeal of the ruling, the latest in a long-running dispute between the two largest commercial plane makers.

In an 850-page report, the Geneva-based trade body accepted a claim by the European Union that research and development grants provided by United States space programs contributed substantially to the technologies used in building the 787, Boeing’s latest flagship aircraft. But it said the amount of prohibited support amounted to a fraction of the more than $19 billion dating back to the late 1980s that Brussels had originally challenged.

Ron Kirk, the United States trade representative, said Washington disagreed with the W.T.O. panel’s findings and was studying options for appeal. He stressed that roughly half of the subsidies condemned by the W.T.O. had been previously remedied by changes in American policy, noting that the panel had recommended the United States withdraw just $2.7 billion in aid to Boeing.

The European Union hailed the W.T.O’s decision as a “landmark ruling.” Karel De Gucht, the bloc’s trade commissioner, called on Washington to “take the appropriate steps that may assist to achieve a mutually agreed solution to this dispute.”

European supporters of Airbus had focused much of their complaint on research contracts that Boeing received from the National Aeronautics and Space Administration and the Pentagon since the late 1970s to develop lightweight carbon composite materials that the manufacturer subsequently used in the design of the Dreamliner. As much as 50 percent of the 787’s primary structure, including the fuselage and wings, is made of composite materials, more than any other large civil aircraft.

Mr. Kirk said $2.6 billion of the subsidies that the panel found were from NASA and that the Pentagon contributed only $110 million. 

In addition, he said, 20 of the 23 claims about Pentagon contracts were rejected, with the panel ruling that they were legitimate procurement contracts rather than research grants. 

In its report, which was submitted confidentially to American and European trade negotiators at the end of January, the W.T.O. largely agreed that, “absent the aeronautics RD subsidies, Boeing would not have been able to launch an aircraft incorporating all of the technologies that are incorporated in the 787.”

It also found that Boeing’s introduction of the 787 program in 2004 had forced Airbus to lower the price of its A330 wide-body aircraft to maintain market share. However, it rejected the claim that the 787 had an impact on the price that Airbus was able to command for its forthcoming challenger to the 787, the A350-XWB.

Several weeks ago, the United States Defense Department awarded Boeing a $35 billion contract to supply the Air Force with new aerial refueling tankers. Analysts said Boeing’s victory in that contest would probably blunt the sting of the W.T.O.’s findings for Boeing’s supporters in Washington and expressed hope that the two sides would eventually move beyond this dispute toward a negotiated settlement.

“It has not been a very edifying spectacle,” said Nick Cunningham, an aerospace analyst and managing partner at Agency Partners, a London-based consultancy. ”It’s a lot of sound and fury signifying very little.”

In a case decided last June, the W.T.O. found that Airbus had benefited from four decades of improper subsidies to vault past Boeing to become the world’s top jet builder.

That ruling, which has been appealed by both sides, concluded that Airbus had received the subsidies, including $15 billion in loans from European governments at below-market interest rates and several billion dollars in grants, to produce the A380 superjumbo and five other best-selling models. But the W.T.O. stopped short of a wholesale condemnation of government loans — known as “launch aid” — that are repaid largely through export sales.

The W.T.O. is expected to rule on the appeal of that ruling next month.

Airbus said in a statement Thursday that it was pleased with the findings of the W.T.O. report but that it expected the European Union to appeal a number of issues relating to legal interpretation.

Analysts said they hoped the publication of the report would bring an epic battle over subsidies in the aircraft industry to a close and eventually pave the way for new set of ground rules among the world’s makers of large civil aircraft — a field that has grown substantially since the United States and European governments began their dispute nearly seven years ago.

Embraer of Brazil and Bombardier of Canada, which for decades have specialized in smaller jets with fewer than 100 seats, have begun to develop larger planes with the range and capacity approaching that of the Airbus A320 and the Boeing 737 — single-aisle planes that are the bread and butter of most of the world’s airlines. Mitsubishi of Japan and United Aircraft of Russia also expect to build planes that can carry up to 200 passengers around the middle of this decade, while China’s C919 jet is projected to enter commercial service in 2016.

Last month, the Irish low-cost carrier Ryanair — which currently operates a fleet of 250 Boeing 737s — confirmed it was talking with the Chinese and Russians, as well as Boeing and Airbus, about future jet orders.

“It’s no longer a bipolar world,” said Mr. Cunningham of Agency Partners. “You can’t go down this puritanical road of no government funding for aerospace. You have five up-and-coming competitors who aren’t going to play that game.”

Single-aisle jets are expected to represent more than half of the roughly $3.6 trillion in anticipated new aircraft sales over the next 20 years, according to industry estimates.

Christopher Drew contributed reporting from New York.

Article source: http://feeds.nytimes.com/click.phdo?i=9aeaf8780b2657267106fd7fb1cb33a7

Irish Banks Need an Additional €24 Billion, Central Bank Says

While largely expected by the market, the total aid figure was still a jarring number — one that increases the total bill for bailing out Ireland’s banks to about €70 billion, or about $99 billion, and increases government control of the banking sector.

The Irish bank losses come amid fresh concerns that Europe’s banking problems are getting worse, not better. In Spain, which is experiencing a real estate collapse similar to Ireland’s, a plan for four troubled savings banks, or cajas, to merge fell through Wednesday, raising concerns there that, as was the case in Ireland, Spain might be underestimating the depth of its banking crisis.

“This has been one of the costliest banking crises in history,” said Patrick Honohan, the governor of the Central Bank of Ireland, which oversaw the stress tests. “There was a need for the banks to have ample capital to meet the markets gloomy prognostications.”

The market’s reaction was for the most part muted. The yield on 10-year Irish bonds rose 0.1 percent point Thursday, to 10 percent, just off the all-time high of 10.3 percent.

Expected or not, the large figure will give the new Irish government fresh ammunition to push more forcefully its view that holders of senior, unsecured bank debt — a security that is riskier in nature than one that is currently guaranteed by the government — should take a loss on their position to ease the state’s punishing debt burden.

So far the European Union and the International Monetary Fund have resisted such a move, arguing that to restructure any amount of debt would be more a political than a practical measure. They also contend that restructuring would create a broader market panic as investors unload not just their Irish holdings, but similar exposure in other weak economies like Greece, Spain and Portugal.

Ireland’s banks relied on the European Central Bank for €88.7 billion of financing at the end of February, the central bank said. The Irish finance minister, Michael Noonan, said Thursday that the E.C.B. had agreed to extend its financing over the medium term to give Ireland’s banks more time to work through their problems.

The €24 billion figure comprises €13.3 billion for Allied Irish Banks, €5.2 billion for Bank of Ireland, and the rest for two smaller institutions, Irish Life Permanent and EBS Building Society. EBS will be folded into Allied Irish, the central bank said.

Also on Thursday, another fallen Irish bank, Anglo Irish, announced the largest loss in the country’s corporate history — €17.7 billion. Anglo Irish, which is expected to receive €34 billion from the state, was not included in the stress test as it is being gradually sold.

Officials of the central bank said the stress test, which was conducted with the U.S. money management firm BlackRock, had come as close as possible to exposing the extent of bad loans still remaining in the system.

“This is as definitive as can be without being categoric,” said one official, who declined to give his name as he was not authorized to speak publicly.

Officials said the process of reducing the Irish funding gap, or the difference between bank deposits and loans, will take years and will require the write-off and disposal of €72 billion in problem loans by 2013.

It will also require a revival of depositor and investor confidence, neither of which seems imminent.

The gap, also known as the loan-to-deposit ratio, now stands at 171 percent against a government goal of 122 percent. The shortfall is being financed by the European Central Bank and the Irish Central Bank to the tune of about €150 billion, an amount that is about equal to the country’s gross domestic product.

Repaying this obligation will be one of the central challenges for the government in the years ahead.

Article source: http://feeds.nytimes.com/click.phdo?i=78e5607741abcbc1fdbdd499ebfc8255

After Japanese Crisis, New Urgency to Develop Radiation Drugs

But the two men — who were injured in a nuclear fuel accident in Japan in 1999, not during the current crisis — did not die right away. Drugs and procedures unavailable when the atomic age began kept Mr. Ouchi alive for 82 days, and Mr. Shinohara for about seven months.

As radiation spreads in Japan from crippled nuclear reactors, with workers at the Fukushima Daiichi nuclear plant potentially exposed to extremely hazardous levels, experts say that progress has been made in developing treatments for radiation poisoning. But there is still much work to do.

The crisis has put a spotlight on some small biotechnology companies developing drugs to treat people exposed to radiation. Some say they are accelerating their efforts in light of the problems in Japan.

Most of the companies are working under contracts from the United States government, aimed at treating people after a military or terrorist attack involving a nuclear or radioactive weapon. Such drugs would also be of use in a nuclear power plant accident, particularly for the nuclear plant workers, who might be exposed to the highest doses.

“There would definitely be a zone around ground zero where you could save a lot of people with these drugs,” said Mark H. Whitnall, program advisor for radiation countermeasures at the Armed Forces Radiobiology Research Institute in Bethesda, Md.

Based on tests using animals, he said, the drugs under development would allow people to survive doses 20 to 40 percent higher than what is now considered lethal. “We’d like to do a lot better,” he said.

The Japanese crisis has caused brief upticks in the shares of some of the companies focusing on this research, like Cleveland Biolabs. Some 5.6 million shares of Aeolus Pharmaceuticals changed hands on a single day after the crisis began, many times the usual trading volume.

“It was crazy, just crazy,” said John McManus, chief executive of the company, which is based in Mission Viejo, Calif. In February, it received a federal contract worth up to $118 million to help it develop a drug to protect the lungs from radiation damage.

Several of the companies say they want to make their drugs available for use in Japan, but the government there has not ordered any. The drugs in question have not been approved by the Food and Drug Administration, and it is unclear whether anyone in Japan, even workers at the Fukushima plant, have been exposed to enough radiation to warrant such treatments.

Most of the drugs in development are two to five years away from possible regulatory approval, federal officials say, and even once approved there would still be some slight uncertainty about how well they would work in people. Because it would be unethical to expose people to high levels of radiation in a clinical trial, the F.D.A. allows approval of this type of drug if it proves effective in two species of animals and is shown to be safe in people at doses corresponding to those used in the animals.

Getting federal support for the research is one thing. It might be tougher to get the federal government to buy large quantities to be stockpiled for use in an emergency.

A cautionary tale is that of Hollis-Eden Pharmaceuticals, which was developing a steroidlike compound that was championed by Defense Department scientists. But in 2007, after the company spent $85 million on development, the Department of Health and Human Services decided not to buy the drug, saying it did not meet technical requirements.

Hollis-Eden’s stock price collapsed and has never recovered. The company dropped the drug and changed its name to Harbor BioSciences.

Some federal officials and experts say that Health and Human Services decided it needed drugs that could be effective even if not given until 24 hours after exposure, reasoning that in the event of a terrorist attack it would be hard to get the drug to people immediately. The Hollis-Eden drug did not meet that requirement.

The department plans a big purchase, but not of an experimental drug developed by a tiny company. Rather, it is looking to buy hundreds of millions of dollars worth of Amgen’s Neupogen or a similar drug, including generic versions of Neupogen that have been approved in Europe, according to Robin Robinson, director of the department’s Biomedical Advanced Research and Development Authority.

Neupogen helps the body build infection-fighting white blood cells, which can be depleted by radiation. The drug is approved to help prevent infections in cancer patients undergoing chemotherapy, but the F.D.A. has issued an “emergency use authorization” that would allow the drug to be used to treat radiation exposure.

Biodefense work has largely fallen to small biotechnology companies because they need the money, especially at a time when investors are averse to risk. Federal research grants can help defray the costs of developing a drug for commercial uses. In the case of radiation treatments, the commercial use would mainly be to protect cancer patients from the side effects of radiation therapy.

“It’s significant funding for a biotech company like ours,” said Ram Mandalam, chief executive of Cellerant, a private company that won a federal contract worth up to $153 million over five years to develop a drug using stem cells to help bolster the immune system after radiation exposure.

Radiation can have various health effects, depending on the dose and form. For nuclear power plant accidents, the major exposure for the public would come from radioactive isotopes, and there already are some approved drugs for these that are in the federal stockpile.

Potassium iodide can help prevent thyroid cancer that can be caused by iodine-131, which has been detected in some milk, produce and tap water in Japan. Elevated levels of radioactive iodine have also been detected in milk in Washington State and California but the levels are still far too low to pose a health threat, the Environmental Protection Agency said on Wednesday. It has stepped up monitoring of radiation levels.

Exposure to cesium-137 can be treated with Prussian blue, a pharmaceutical version of an industrial dye, while plutonium exposure can be treated with DTPA. Both drugs bind to the isotopes and help the body to excrete them.

Article source: http://feeds.nytimes.com/click.phdo?i=58928f3b23e5b8624e5f4ee3fc399226

DealBook: In Berkshire Resignation, Perception Matters

David L. SokolNati Harnik/Associated PressDavid L. Sokol

Perception is more important than reality.

After watching David L. Sokol on Thursday morning on CNBC as he tried to explain some potentially questionable trades he made in Lubrizol before Berkshire Hathaway bought the company, I was struck by what appeared to be a remarkable lack of appreciation for the way the public would perceive his actions.

Mr. Sokol clearly appeared to believe he had not done anything wrong or broken any rules when he bought shares of Lubrizol on Dec. 14, just a day after he instructed Citigroup to set up a meeting on behalf of Berkshire Hathaway to potentially orchestrate an acquisition of the company.

I have met Mr. Sokol before, found him to be an honest man and take his word that he thought he had acted completely appropriately.

But the facts paint an unattractive picture that creates a public perception problem — even if the reality of the situation is more innocent (I don’t know if it is or isn’t).

DealBook Column
View all posts




At the time Mr. Sokol personally bought shares of Lubrizol, he had already begun trying to set in motion the gears of an acquisition by instructing Citigroup to put together a meeting with Lubrizol’s chief executive. Mr. Sokol, of course, had no way to know whether Lubrizol would engage in talks or whether Warren E. Buffett and Berkshire Hathaway’s board would be interested in acquiring the company.

But in the court of public opinion that doesn’t matter. His intent was to recommend the deal to Mr. Buffett. And even though he had no control over Mr. Buffett’s ultimate decision, he was one of a select few who were in a position to influence such a transaction.

Perhaps most striking, Mr. Sokol said on Thursday morning that if he could do it again, he would have bought shares of Lubrizol but not subsequently suggested that Mr. Buffett buy the company.

Putting aside the legality of the trade — and several lawyers I have spoken with believe the S.E.C. will scrutinize this matter seriously — the transactions demonstrate poor judgment.

Mr. Buffett once said: “Contemplating any business act, an employee should ask himself whether he would be willing to see it immediately described by an informed and critical reporter on the front page of his local paper, there to be read by his spouse, children and friends.”

That is a good rule to live by.

11:27 a.m. | Updated
After publishing my column, I received an e-mail asserting that Mr. Sokol “broke the spirit of the law,” and wondering how I could accept his defense. Let me clarify my point.

Do I believe that Mr. Sokol thought he hadn’t done anything wrong? Absolutely. Do I also believe that Mr. Sokol is naïve if he doesn’t understand how his trading could be problematic? Absolutely.

These two points are not mutually exclusive. If anything, the interview demonstrated that he did seem to understand the spirit of the rules.

Perhaps the most troubling part is that Mr. Sokol was out for himself, rather than for Berkshire. If he could have done it again, Mr. Sokol said he would have still bought shares in Lubrizol, but not recommended it as an acquisition target to Mr. Buffett — for which he said Berkshire would have been the loser.


Andrew Ross Sorkin is the editor of DealBook.

Article source: http://feeds.nytimes.com/click.phdo?i=0e224ca6942d00fecbe3fe15e39cdc19

The Fed’s Crisis Lending: A Billion Here, a Thousand There

WASHINGTON — The Federal Reserve lent billions of dollars to the nation’s largest banks during the financial crisis in the fall of 2008. It also lent $400,000 to the Eudora Bank, a community lender with a single location in the center of Eudora, Ark.

Day after day in late October and early November, near the high-water mark of the Fed’s efforts to rescue Wall Street, the central bank also made dozens of similarly modest loans to small banks in communities across the country.

Some banks, like Howard Bank, a suburban lender with four offices outside Baltimore, borrowed as little as $1,000 — a fire drill in case things got worse.

Other borrowers already were facing dire problems. Several have since failed, including La Jolla Bank in Southern California, which took $6 million.

The Fed released a complete list Thursday of banks that borrowed during the crisis from its discount window, its oldest and broadest emergency lending program. The central bank already released similar information for its other lending programs.

As with those other programs, the discount window mostly served the giant banks like Bank of America, Citigroup and Washington Mutual, whose struggles to survive the consequences of reckless lending and investment have defined the narrative of the crisis.

But the discount window was unique because it was open to smaller banks, too. The other emergency programs were created during the crisis to support the trading and investment activities that are concentrated in New York. The discount window, which predates the crisis by almost a century, was created to help commercial banks weather cash squeezes.

The long list of banks that lined up at the window, which the Fed provided in the form of a daily loan register, shows a crisis stretching far beyond Wall Street.

On Wednesday, Oct. 29, 2008, for example, the Fed lent money to 60 different banks, in amounts ranging from $1,000 to $26.5 billion.

At least 10 of those banks have since failed.

Borrowing from the discount window is considered a sign of weakness, and banks historically have avoided it if they can. From 2003 through 2006, the Fed lent an average of less than $50 million each week.

By the summer of 2007, however, the central bank was increasingly concerned that a growing number of banks needed help but were unwilling to borrow. In August, the Fed slashed the cost of borrowing from the discount window by half a percentage point. Then it arranged for four of the nation’s largest banks, Bank of America, Citigroup, JPMorgan Chase and Wachovia, to take what were described as symbolic loans of $500 million.

By the peak of the crisis in late October and early November 2008, the volume of outstanding discount window loans reached above $100 billion.

The Fed has long treated its interactions with banks as confidential but a series of federal courts ruled that it had to provide information on its emergency lending programs in response to Freedom of Information Act requests filed more than two years ago by Bloomberg News and the Fox Business Network.

The Fed provided the data to reporters Thursday in the form of several hundred electronic images of the original documents, loaded on a compact disc, distributed by hand at 10 a.m. in the cramped security checkpoint outside its headquarters building.

By contrast, the Fed released data on its other emergency lending programs in December by creating a public, searchable Web site.

Bankers have expressed concerns about the release of the data, saying that the prospect of publicity will deter future borrowing.

“I think it will make it harder for people to use the discount window in the future,” Jamie Dimon, chief executive of JPMorgan Chase, said Wednesday.

Article source: http://feeds.nytimes.com/click.phdo?i=cd6ca9c035e6a4ad328861fbeca0bc2c

Advertising: In Bid for Young Viewers, Baseball Ads Swap Action for Funny Videos

Take me out with, like, all my Facebook friends

Buy me some brewskis, for sure, and, like, maybe some Crackerjack?

I don’t care if, like, I never get back, if I can bring my iPad, iPhone and, um, BlackBerry with me.

O.K., O.K., so Major League Baseball, in its newest effort to reach out to younger potential fans, will not be rewriting the lyrics to its anthem. Instead, the league is introducing, beginning with the start of the 2011 season on Thursday, an ambitious campaign aimed at the demographic aged 18 to 34.

The campaign is the first for Major League Baseball from its new creative agency, Hill, Holliday, Connors, Cosmopulos in Boston, part of the Interpublic Group of Companies. Not only are the tone and approach different from previous campaigns, which took more traditional tacks, but the ads will have a far larger presence in social media that younger Americans adore, like Facebook and Twitter.

•

One way the campaign tries to woo younger fans is by replacing the previous theme, “Beyond baseball,” with the phrase “MLB Always epic”; there will also be a microsite called mlbalwaysepic.com.

There is clearly a double use of the word “epic,” said Tim Brosnan, executive vice president for business at Major League Baseball in New York, reflecting popular slang phrases like “Dude, this is epic,” as well as the idea that “there are stories that contribute to the epic nature of baseball and over the course of a season baseball has an epic sweep, if you will.”

In another attempt to appeal to a more youthful audience, the campaign is changing the look of commercials and video clips. Formerly, spots celebrated the charms of baseball as a sport by offering glimpses of in-game action. The new commercials, on TV and online, offer humorous vignettes of popular players. In one spot, viewers are invited to visit the microsite for “a journey inside” the bushy beard of the reliever Brian Wilson of the San Francisco Giants.

In a second commercial, the pitcher Felix Hernandez of the Seattle Mariners, who won the Cy Young Award last year, is shown winning all the stuffed animals at the Milk Jug Toss booth at a carnival. The carny inside the booth, disgusted, pulls the plug — literally — on the pitcher.

In a third spot, Ubaldo Jiménez, a pitcher for the Colorado Rockies, browses the racks of miniature souvenir license plates at a gift shop but — surprise! — cannot find one that reads “Ubaldo.” A teammate frets, “The bus is waiting,” but Mr. Jiménez asks, “Do you have any more in the back?”

Major League Baseball sponsors and partners like Pepsi-Cola and Fox Broadcasting have long centered campaigns on star players. So, too, have leagues for other sports like basketball and football; for example, a fanciful new “time travel” campaign for the National Basketball Association features players like Steve Nash.

But M.L.B. has shied from that because far more players have local or regional profiles than national stature.

“I’ve always been a proponent of emphasizing the personalities of the athletes,” said Bob Dorfman, executive creative director at Baker Street Advertising in San Francisco, who tracks the value of players as endorsers.

“There aren’t as many big, national names in baseball because you tend to root for your local team,” Mr. Dorfman said, “but it makes sense to have fun with players, try to make them more attractive, so maybe you’ll get out to a game you wouldn’t otherwise see.”

As for seeking younger fans to fill seats at ball parks, Mr. Dorfman said: “That’s a problem baseball has had, the aging of its market, the idea that the game is too slow for the social media generation. It’s worth trying to get that teenage and 20-something audience to think that baseball is cool.”

Mr. Brosnan said that “the commitment we ask our fans to make is pretty intense,” and millions say yes each season.

“We want to be a part of the discussion at the digital water cooler, day in and day out, with a younger demo than we’ve targeted in our advertising before,” Mr. Brosnan said. “And the nature of this campaign is to help them spread the word.”

Hill, Holliday landed the M.L.B. account last fall after the league parted ways with its previous creative agency, McCann Erickson Worldwide in New York, part of the McCann Worldgroup unit of Interpublic.

“When we pitched the business, the approach we took was that baseball has all the qualities for the modern entertainment era,” said Karen Kaplan, president at Hill, Holliday, because like the Harry Potter books and movies, “Lost” and “Mad Men,” baseball has “long-running story arcs, legends, back stories, rivalries and sprawling casts of characters, heroic characters you should be interested in, even if they don’t play for your team.”

“Some things people might consider liabilities are actually assets,” she said.

The focus on players “drives engagement,” Ms. Kaplan said, by capitalizing on them as “content engines,” providing grist for the social media mill with comments and videos to be shared through social networks.

That is also the idea behind the MLB Fan Cave, developed by Hill, Holliday; Endemol USA; and Major League Baseball. Mike O’Hara, 37, and Ryan Wagner, 25, will watch the 2011 baseball season unfold from the old Tower Records store at East Fourth Street and Broadway in Manhattan, sharing their thoughts through Twitter (@MLBFanCave), a blog on mlb.com, Facebook, video clips and appearances on the MLB Network cable channel.

The campaign will also appear on the MLB Network, Fox, ESPN and TBS, along with related Web sites.

•

The start of the new season is bringing other baseball-related campaigns that speak with hipper voices.

Old Style beer, sold by the Pabst Brewing Company, is introducing a campaign by Scott Victor in Chicago that plays up the brand’s sponsorship of the Chicago Cubs and its bottles designed to resemble bats.

The ads carry cheeky headlines like “Crack a bat,” “Tossed back by Cubs fans for 61 years” and, referring to Wrigley Field, “We were there when the ivy wall was more wall than ivy.”

And StubHub, the online ticket reseller, is bringing out a campaign by Duncan/Channon in San Francisco that includes its first national TV commercials.

In one spot, as an organ plays “Take Me Out to the Ball Game,” young men romp through a fantasy field of dreams; after a team mascot helps one catch a fly, he lands on grass carpeted with hot dogs.

Article source: http://feeds.nytimes.com/click.phdo?i=e1fdef97c4583eb7ef75c5eff1ebfbc0

Room For Debate: Is This Tech Boom Different?

Introduction

tech bubbleEd Nacional

With Wall Street banks, venture capitalists, hedge funds and private equities all wanting a piece of the latest technology funds or Internet start-ups, the tech industry is enjoying a flood of money. In the last two years, valuations for Facebook but also for the game maker Zynga have more than quintupled. Groupon, the social shopping site, saw its estimated value soar from $1.4 billion to $25 billion.

Some financial analysts fear there is a new bubble, like the dot-com boom and bust in the late 90’s. What are the lessons from that era? What are the similarities and differences?

 Read the Discussion »

<!–

Topics: Facebook, Internet, Technology

–>

Article source: http://feeds.nytimes.com/click.phdo?i=a2b5bceecce44d3b891da7d91d03d256

Special Section: Energy


Video


Pinnacle’s Opposed Piston Engine

In this design, two pistons face each other, the space between them forming a combustion chamber. Eliminating the traditional cylinder head results in a lighter, cheaper and more efficient engine.

Article source: http://feeds.nytimes.com/click.phdo?i=f4c50926c81ec022a5060cd200b10569

State of the Art: The Cloud That Rains Music

Amazon, whose online music store competes with Apple’s, has two problems with that arrangement. First, your music library is messily scattered. When you buy a new song at home, you can’t listen to it at work, at least not without copying it manually. You might buy a song on your phone, but it won’t be on your computer until you do a sync. And if your music library is big, you can fit only a portion of it onto your phone.

Second, Amazon wishes more people would buy music from its store instead of iTunes.

This week, the online retailer took the wraps off a slick suite of software and services that solves both problems, and offers some sweet incentives for you to consider it.

Amazon’s big idea is that instead of sitting on your computer, your music collection will sit online ( or “in the cloud,” as hipsters insist on saying). That way, you can listen to it from any computer — at home, at work, at a friend’s — by logging into a special Web page called the Amazon Cloud Player.

You can also listen to anything in your music collection on an Android phone. No copying or syncing of music is ever required; all your songs are always available everywhere, and they don’t hog any storage on the phone itself.

The Cloud Player is a simple, clean, polished music-playback page that looks vaguely like iTunes. It’s dominated by a list of your songs, which you can sort and search. The album art shows up. You can drag songs into playlists. You can play back a song, album or playlist, complete with Shuffle and Repeat functions. You can download songs to your computer (they go directly into iTunes or Windows Media Player). Sound quality is excellent (the streaming is the full 256 kilobits a second of the original files, if you’re into that sort of statistic).

There’s a free Uploader app that lets you send your existing music files from your Mac or PC to that same online library, so those songs, too, are available from anywhere. The app is clever enough to preserve your songs and playlists the way you organized them in iTunes or Windows Media Player. (Just note that it recognizes only MP3 and AAC files — not ring tones, audio books or WAV files. Copy-protected songs need not apply.)

The app for Android phones is similar. It offers two big buttons: one for listening to your online music collection, and another for playing the music files that are actually on the phone. There’s no way to mix and match — to create a playlist containing some songs from each source, for example.

Amazingly enough, all of this is absolutely free.

Well, sort of.

Songs are pretty big files. That, after all, is one huge advantage of Amazon’s cloud idea: moving those hefty music files to the Internet frees up space on your computers and phones.

To get you started, Amazon offers everyone five gigabytes of free space online — enough room for about 1,200 MP3 songs. You can buy more storage; it costs $1 a gigabyte a year. If you have a 50-gigabyte song collection, for example, you’ll pay $50 a year. That can get awfully steep at the high end (like $1,000 for 1,000 gigabytes) — high enough to make “pay $15 a month for unlimited music” sites like Rhapsody look awfully appealing.

The storage is good for more than music files, though. Part II of the Amazon announcement is the Cloud Drive, an online hard drive a lot like the Apple iDisk or Microsoft SkyDrive.

On this virtual drive, you can store anything at all: photos, Office documents — anything you might like to back up or to retrieve later from any other computer. Even if you never use any of Amazon’s music features, having this five-gigabyte drive online is a pleasant surprise, free to anyone who wants it. (You can view the photos and play the music you’ve stored there, but otherwise, it’s just a place for parking files, not opening them.)

Amazon takes the sting out of its storage prices with some special offers. For example, if you buy an album from Amazon’s music store, your Cloud Drive gets bumped up to 20 gigabytes for the year — no charge.

E-mail: pogue@nytimes.com

Article source: http://feeds.nytimes.com/click.phdo?i=9525c0034f32b935bdd650fb7ca5b8ea

A Book for Sale on Tax Day, but Online Now

Except that’s not really when it went on sale.

Amazon and Barnes Noble were selling the book on their Web sites on Wednesday, long before many bookstores would receive copies. Nicole Dewey, a spokeswoman for Little, Brown, part of Hachette, said the official on-sale date for the book was March 22, but the publication date — when the book is available everywhere — remained April 15. (A countdown clock on the Hachette Web site ticks away the days, hours and minutes until April 15.)

“I don’t really understand the confusion,” Ms. Dewey said. “This happens all the time. There’s nothing unusual about it.”

It was a distinction lost on many bookstores, who erupted in protest on Wednesday when they heard that Amazon was already selling the hotly anticipated book.

“Outrageous,” said Zack Zook, the general manager and events coordinator at BookCourt, an independent store in Brooklyn. “If stuff like this keeps happening, booksellers are going to start suing publishers.”

Kelly von Plonski, the owner of Subterranean Books in St. Louis, said she was “irate” after hearing on Wednesday that the book was already on sale. She had planned a midnight release party for April 14, the night before she thought the book was being released.

“I’m really, really angry about it,” she said. “Add it to the list of advantages that Amazon has been given.”

Countless stores were left flat-footed.

While Barnes Noble was selling the book on its Web site, several of its outlets in Manhattan and Brooklyn said they had not yet received copies and were not allowed to sell them until April 15.

At Vroman’s Bookstore in Pasadena, Calif., not far from Pomona College, where Mr. Wallace was a professor in the English department when he died, the store had ordered 55 copies but was waiting to put them on display.

Paul Yamazaki, the head buyer at City Lights bookstore in San Francisco, said he had been told “The Pale King” had a strict on-sale date of April 15.

Several distributors told booksellers this week that they would not ship them copies because it was too far away from the publication date in April.

Publishers try to get books in stores by the time media coverage begins, usually before the official publication date. Time magazine is expected to run a lengthy article about “The Pale King” in its next issue.

Mr. Wallace, whose best-known book was “Infinite Jest,” committed suicide in 2008 at the age of 46.

He has since become somewhat of a cult figure, and fan sites devoted to him were abuzz on Wednesday with news that the book had started shipping from Amazon.

Article source: http://feeds.nytimes.com/click.phdo?i=0b57d85a9be442b80ae10bb06322d8f1